LY-311727

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameLY-311727
Drug Alias NameLY-311727
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCytosolic phospholipase A2 inhibitors
TargetsCytosolic phospholipase A2
Therapy Area/IndicationsSepsis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesPoland +[5] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEli Lilly And Company
Active IndicationsN/A
Inactive IndicationsSepsis

Other Information

ATC CodeN/A
Related LinksN/A